Start-up 10x Science aims to streamline drug development with AI-powered platform
The impact of AI in scientific research has been significant, particularly in the field of drug development. One notable example is Google DeepMind’s use of a deep learning model to predict protein structures. However, as more potential treatments are identified through AI models, there’s an emerging challenge: char…
Enter 10x Science, a start-up founded by three experienced researchers who met while working at Stanford University. The team, comprising David Roberts and Andrew Reiter, both biochemists, and Vishnu Tejas, a serial founder with expertise in computer science and AI models, aimed to address this bottleneck.
The characterization process is crucial for drug development as it helps determine the structure of proteins, which are essential for creating biologic drugs. These drugs are produced in living cells and designed to target specific diseases or conditions. A notable example is Keytruda, a popular cancer treatment dev…
Characterizing molecules is a complex task that typically involves mass spectrometry, a technique that generates significant data requiring expertise to interpret. This process can be time-consuming and often hinders the development of new treatments. To address this challenge, 10x Science has created an AI-powered…
What matters
- Combines deterministic algorithms with AI agents for data interpretation
- Aims to simplify characterization process of potential drugs
- Founded by experienced biochemists and computer science expert
Why it matters
Founded by experienced biochemists and computer science expert
This GenAI News article was prepared in original wording using reporting and materials published by TechCrunch AI. Source reference: https://techcrunch.com/2026/04/22/ai-is-spitting-out-more-potential-drugs-than-ever-this-start-up-wants-to-figure-out-which-ones-matter/.
Drafted by the GenAI News review pipeline.